Posted by: ihfgeneva | May 22, 2013

A dialogue on Biosimilar Medicines

The International Hospital Federation proudly participated in a Workshop on Biosimilar Medicines organized by the International Alliance of Patients´ Organizations (IAPO).

Through various sessions, that took place in a 2 day period, key representative members of international patients´ organizations, along with important healthcare stakeholders, discussed their experiences with biological and biosimilar medicines.

Biological medicines are different of traditional chemical medicines because they are made from a living organism, while biosimilar medicines are highly similar versions based on the same active ingredients as the original biological medicine.

Since their introduction, they have become primary treatments for conditions such as cancers, diabetes, heart attacks, autoimmune deseases and others.

Jo Groves, CEO of IAPO, introduced the workshop by stating the expectations and challenges for the use of biosimilar medicines, explaining there is a real need for healthcare to engage in this subject as there has been an increased use and development of these type of medicines.

Subjects like how biosimilar medicines adress current and future needs or the learning and best practices to facilitate patient acces to biological medicines were presented to attending members, as well as allowing time for discussion and debate.

IAPO took this dialogue as an opportunity to obtain feedback on the participants for their draft Briefing Paper on Biosimilar Medicines which aims to give patients´ organizations useful and detailed information about these medicines.

The workshop had speakers from important healthcare institutions such as the World Health Organization, Finnish Medicines Agency and the Alliance for Safe Biologic Medicines.

The dialogue became a successful platform for health stakeholders and patients´organizations to create a solid base from which to develop conscience about this important issue and to consolidate plans of action and regulatory guidelines in the use and access of biological medicines.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: